Silla L M, Whiteside T L, Ball E D
Division of Hematology/Bone Marrow Transplantation, University of Pittsburgh Medical Center, PA, USA.
J Hematother. 1995 Aug;4(4):269-79. doi: 10.1089/scd.1.1995.4.269.
The success of chemotherapy in patients with leukemia whose marrow appears to be replaced by leukemia cells must be due to the persistence of normal stem cells. In this normal population are the progenitors of the cells of the immune system. Natural killer (NK) cells originate in the bone marrow. On maturation and activation with interleukin 2 (IL-2) or other cytokines, NK cells develop cytotoxic activity against a variety of leukemic blasts, including those from patients with chronic myeloid leukemia (CML). In the past few years, bone marrow transplantation (BMT) and alpha-interferon (IFN-alpha) have proved to be the most promising therapies for the treatment of CML. In both these therapies, NK cells may play a prominent role. In this article, we discuss the antitumor/antileukemia activity of human NK cells, the presence of benign NK cell precursors in the different stages of CML, the role of NK cells in BMT and IFN-alpha treatment, and the potential therapeutic applications of NK cells in patients with hematologic malignancies.
对于骨髓似乎被白血病细胞取代的白血病患者，化疗的成功必定归因于正常干细胞的持续存在。在这个正常细胞群体中，存在着免疫系统细胞的祖细胞。自然杀伤（NK）细胞起源于骨髓。在白细胞介素2（IL-2）或其他细胞因子的作用下成熟并激活后，NK细胞会对多种白血病母细胞产生细胞毒性活性，包括慢性髓性白血病（CML）患者的白血病母细胞。在过去几年中，骨髓移植（BMT）和α干扰素（IFN-α）已被证明是治疗CML最有前景的疗法。在这两种疗法中，NK细胞可能都发挥着重要作用。在本文中，我们将讨论人类NK细胞的抗肿瘤/抗白血病活性、CML不同阶段良性NK细胞前体的存在情况、NK细胞在BMT和IFN-α治疗中的作用，以及NK细胞在血液系统恶性肿瘤患者中的潜在治疗应用。
